Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB, Berti E, et al. Correction: "The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms" Leukemia. 2022 Jul;36(7):1720-1748. Leukemia. 2023;37(9):1944-1951.

Mesa KR, O'Connor KA, Ng C, Salvatore SP, Littman DR. Niche-specific macrophage loss promotes skin capillary aging. bioRxiv. 2023.

Stopsack KH, Su XA, J Vaselkiv B, Graff RE, Ebot EM, Pettersson A, et al. Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions. Mol Cancer Res. 2023;21(1):14-23.

Hao Y, Lynch K, Fan P, Jurtschenko C, Cid M, Zhao Z, et al. Development of a Machine Learning Algorithm for Drug Screening Analysis on High-Resolution UPLC-MSE/QTOF Mass Spectrometry. J Appl Lab Med. 2023;8(1):53-66.

Liu D, Cheng Y, Zhou H, Wang L, Fiel RH, Gruenstein Y, et al. Early Introduction and Community Transmission of SARS-CoV-2 Omicron Variant, New York, New York, USA. Emerg Infect Dis. 2023;29(2):371-380.

Barone P, Patel S. Myelodysplastic syndrome: Approach to diagnosis in the era of personalized medicine. Semin Diagn Pathol. 2023;40(3):172-181.

Alhomoud M, Magro C, Seshan S, Zhang T, Gomez-Arteaga A, Chokr N, et al. Deposition of complement components C5b-9 and MASP2 in tissues is not a feature of GVHD and may assist in discriminating GVHD from thrombotic microangiopathy following allogenic transplantation. Bone Marrow Transplant. 2023;58(11):1270-1274.

Pan E, Xie W, Ajmera A, Araneta A, Jamieson C, Folefac E, et al. A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE). Mol Cancer Ther. 2023;22(4):511-518.

Geyer JT, Kluk MJ. Current Landscape of Ancillary Diagnostic Testing in Chronic Lymphocytic Leukemia. Surg Pathol Clin. 2023;16(2):411-421.

Ruan J, Moskowitz A, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, et al. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood. 2023;141(18):2194-2205.